

## Cleansing Notice under section 708A(5)(e) of the Corporations Act

This notice is given by Microba Life Sciences Limited (ASX: MAP) (**Microba** or **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

On 23 June 2025, Microba announced a capital raise to the ASX consisting of:

A placement to raise \$12.5 million before costs by the issue of approximately 138,888,889 ordinary shares (New Shares) at \$0.09 per New Share, plus approximately 69,444,444 unlisted free-attaching options (New Options) on the basis of one (1) New Option for every two (2) New Shares subscribed for under the placement (Placement).

The Placement will complete in two tranches, with 67,177,796 New Shares issued under tranche 1 of the Placement on 27 June 2025 (**Tranche 1 Placement Shares**), 71,711,093 New Shares issued under tranche 2 of the Placement (**Tranche 2 Placement Shares**) and 69,444,384 New Options issued under tranche 1 and tranche 2 of the Placement issued on 13 August 2025 (**Tranche 1 & 2 Placement Options**).

• A fully underwritten share purchase plan to eligible Microba shareholders to raise up to a further \$2.0 million (before costs) by way of the issue of New Shares at \$0.09 per New Share, plus free-attaching New Options on the basis of one (1) New Option for every two (2) New Shares subscribed for under the share purchase plan (SPP Offer). The SPP Offer closed raising the full \$2.0 million and 22,222,168 New Shares and 11,111,039 New Options were issued on Wednesday, 13 August 2025.

The Tranche 2 Placement Shares were issued on 13 August 2025 and an Appendix 2A has been lodged with the ASX for quotation of those Tranche 2 Placement Shares.

## **Details of the Placement**

Details of the issue of Tranche 2 Placement Shares is provided below:

Class of Securities:	Tranche 2 Placement Shares are fully paid ordinary shares
ASX Code of the securities:	ASX : MAP
Date of the issue:	13 August 2025
Total number of Tranche 2 Placement Shares:	71,711,093

In accordance with section 708A(6) of the Corporations Act, Microba gives notice that:

- the Tranche 2 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- this notice is being given under section 708A(5)(e) of the Corporations Act;
- as of the date of this notice, the Company has complied with:
  - o the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - o sections 674 and 674A of the Corporations Act; and
- as of the date of this notice, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.



## **ASX Announcement**

13 August 2025



Authorised for release by the Chair & Chief Executive Officer

For further information, please contact:

**Dr Luke Reid**Chief Executive Officer
<a href="mailto:luke.reid@microba.com">luke.reid@microba.com</a>

Investor / Media Relations investor@microba.com https://ir.microba.com/welcome

## **About Microba Life Sciences Limited**

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit <a href="https://www.microba.com">www.microba.com</a>

